Lexicon Pharma (LXRX) Misses Q2 EPS by 4c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Lexicon Pharma (LXRX) to Resume Trading at 7:45 a.m.
July 30, 2020 7:42 AM EDTLexicon Pharma (NASDAQ: LXRX) to Resume Trading at 7:45 a.m.
... MoreLexicon Pharma (LXRX) Realigns Business Around Research and Development Assets, with Focus on Phase 2 LX9211 Neuropathic Pain Program
July 30, 2020 7:42 AM EDTLexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it is realigning its business around its research and development assets, with a focus on its LX9211 neuropathic pain program, now in Phase 2 clinical development. In that regard:
Initiation of Phase 2 Clinical Development of LX9211. Lexicon has initiated patient screening in RELIEF-DPN-1, a Phase 2 randomized, placebo-controlled,... More
Lexicon Pharma (LXRX) Announces Sale of XERMELO for $159 Million
July 30, 2020 7:11 AM EDTLexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) and TerSera Therapeutics LLC announced today that they have entered into an asset purchase and sale agreement for the sale to TerSera of Lexicons rights, title and interest in XERMELO® (telotristat ethyl).
Pursuant to the terms of the agreement, TerSera will pay Lexicon approximately $159 million in cash at closing, which includes a $155 million upfront... More
Lexicon Pharma (LXRX) Halted, News Pending
July 30, 2020 6:58 AM EDTLexicon Pharma (NASDAQ: LXRX) Halted, News Pending
... More